These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24162592)

  • 21. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
    Yap DY; Tang CS; Yung S; Choy BY; Yuen MF; Chan TM
    Transplantation; 2010 Aug; 90(3):325-30. PubMed ID: 20562676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory T-cell responses in chronic hepatitis B patients treated with nucleos(t)ide analogs compared with healthy subjects and untreated infected individuals.
    Chen LY; Zhu LY; Yang BS; Bi MR; Yan BZ; Wang W; Ma YJ
    Hepatogastroenterology; 2012; 59(120):2582-6. PubMed ID: 22626879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.
    Lampertico P
    J Hepatol; 2009 Apr; 50(4):644-7. PubMed ID: 19231017
    [No Abstract]   [Full Text] [Related]  

  • 24. Hepatitis B--preventable and now treatable.
    Hoofnagle JH
    N Engl J Med; 2006 Mar; 354(10):1074-6. PubMed ID: 16525145
    [No Abstract]   [Full Text] [Related]  

  • 25. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
    Chien RN
    J Gastroenterol Hepatol; 2010 May; 25(5):852-7. PubMed ID: 20546437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic hepatitis B--new goals, new treatment.
    Lai CL; Yuen MF
    N Engl J Med; 2008 Dec; 359(23):2488-91. PubMed ID: 19052131
    [No Abstract]   [Full Text] [Related]  

  • 29. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
    Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Another oral antiviral treatment, but still far away from hepatitis B virus cure.
    Tseng TC
    Clin Mol Hepatol; 2021 Apr; 27(2):281-282. PubMed ID: 33687857
    [No Abstract]   [Full Text] [Related]  

  • 31. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
    Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
    Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
    Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
    J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
    Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E
    Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral options for the treatment of chronic hepatitis B.
    Osborn MK; Lok AS
    J Antimicrob Chemother; 2006 Jun; 57(6):1030-4. PubMed ID: 16595637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of the therapeutical effects of entecavir and lamvudine in treatment of HBeAg-positive chronic hepatitis B].
    Hou HB; Deng LN; Li CP; Liu XR; Liu FQ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):873-4. PubMed ID: 19958652
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment and selection criteria for chronic hepatitis B].
    Gunji T; Omata M
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():309-12. PubMed ID: 15453336
    [No Abstract]   [Full Text] [Related]  

  • 39. Editorial: Measurement of HBsAg concentration during antiviral therapy of hepatitis B: who, when, and why.
    Perrillo R
    Am J Gastroenterol; 2011 Oct; 106(10):1774-6. PubMed ID: 21979203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
    Wang JC; He LL; Chen Q
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.